Literature DB >> 23136597

Therapeutic effects of γ-irradiation in a primary effusion lymphoma mouse model.

Yoshioki Shiraishi1, Kumiko Gotoh, Tomomi Towata, Tatsuya Shimasaki, Shinya Suzu, Akihiro Kojima, Seiji Okada.   

Abstract

Primary effusion lymphoma (PEL) is a unique and recently identified non-Hodgkin's lymphoma in immunocompromised individuals. PEL is caused by the Kaposi sarcoma-associated herpes virus/human herpes virus 8 (KSHV/HHV-8) and has a peculiar presentation involving liquid growth in the serous body cavity, chemotherapy resistance and poor prognosis. In search of a new therapeutic modality for PEL, we examined the effect of γ-irradiation on PEL-derived cell lines (BCBL-1, BC-1, and BC-3) in vitro and in vivo. An MTT assay and trypan blue exclusion assay revealed that irradiation significantly suppressed cell proliferation in the PEL cell lines in a dose-dependent manner, and induced apoptosis. The PEL cell lines were relatively radiosensitive compared with other hematological tumor cell lines (Raji, Jurkat, and K562 cells). Inoculation of the BC-3 cell line into the peritoneal cavity of Rag2/Jak3 double-deficient mice led to massive ascites formation, and subcutaneous injection of BCBL-1 led to solid lymphoma formation. Total body irradiation (4 Gy × 2) with bone marrow transplantation resulted in the complete recovery of both types of PEL-inoculated mice. These results suggest that total body irradiation with bone marrow transplantation can be successfully applied for the treatment of chemotherapy-resistant PEL.

Entities:  

Year:  2010        PMID: 23136597      PMCID: PMC3490335          DOI: 10.3892/etm_00000014

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  35 in total

1.  Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus.

Authors:  R G Nador; E Cesarman; A Chadburn; D B Dawson; M Q Ansari; J Sald; D M Knowles
Journal:  Blood       Date:  1996-07-15       Impact factor: 22.113

Review 2.  Evolving role of radiation therapy for hematologic malignancies.

Authors:  Chung K Lee
Journal:  Hematol Oncol Clin North Am       Date:  2006-04       Impact factor: 3.722

Review 3.  Radiotherapy in non-Hodgkin lymphomas.

Authors:  M Gospodarowicz
Journal:  Ann Oncol       Date:  2008-06       Impact factor: 32.976

4.  Gene induction by gamma-irradiation leads to DNA fragmentation in lymphocytes.

Authors:  K S Sellins; J J Cohen
Journal:  J Immunol       Date:  1987-11-15       Impact factor: 5.422

5.  In vitro radiation-induced apoptosis and early response to low-dose radiotherapy in non-Hodgkin's lymphomas.

Authors:  B Dubray; C Breton; J Delic; J Klijanienko; Z Maciorowski; P Vielh; A Fourquet; J Dumont; H Magdelenat; J M Cosset
Journal:  Radiother Oncol       Date:  1998-02       Impact factor: 6.280

6.  The human herpes virus 8-encoded viral FLICE inhibitory protein physically associates with and persistently activates the Ikappa B kinase complex.

Authors:  Li Liu; Michael T Eby; Nisha Rathore; Suwan K Sinha; Arvind Kumar; Preet M Chaudhary
Journal:  J Biol Chem       Date:  2002-02-05       Impact factor: 5.157

7.  Bortezomib (PS-341) in patients with human herpesvirus 8-associated primary effusion lymphoma.

Authors:  Emmanuelle Boulanger; Véronique Meignin; Eric Oksenhendler
Journal:  Br J Haematol       Date:  2008-03-13       Impact factor: 6.998

8.  Failure to eradicate AIDS-associated primary effusion lymphoma with high-dose chemotherapy and autologous stem cell reinfusion: case report and literature review.

Authors:  Tom W Waddington; David M Aboulafia
Journal:  AIDS Patient Care STDS       Date:  2004-02       Impact factor: 5.078

9.  Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas.

Authors:  J An; Y Sun; M Fisher; M B Rettig
Journal:  Leukemia       Date:  2004-10       Impact factor: 11.528

10.  Combined chemotherapy including high-dose methotrexate in KSHV/HHV8-associated primary effusion lymphoma.

Authors:  Emmanuelle Boulanger; Marie-Thérèse Daniel; Félix Agbalika; Eric Oksenhendler
Journal:  Am J Hematol       Date:  2003-07       Impact factor: 10.047

View more
  2 in total

Review 1.  Current status of treatment for primary effusion lymphoma.

Authors:  Seiji Okada; Hiroki Goto; Mihoko Yotsumoto
Journal:  Intractable Rare Dis Res       Date:  2014-08

Review 2.  Human Herpesvirus Type 8-associated Large B-cell Lymphoma: A Nonserous Extracavitary Variant of Primary Effusion Lymphoma in an HIV-infected Man: A Case Report and Review of the Literature.

Authors:  William R Foster; Alina Bischin; Russell Dorer; David M Aboulafia
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-04-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.